Posterior reversible encephalopathy syndrome

Malaysian haemato-oncological paediatric case series

Choong Yi Fong, Chaw Su Hlaing, Aye Mya Min Aye, Chee Geap Tay, Hany Ariffin, Lai Choo Ong

Research output: Contribution to journalArticle

Abstract

Background & Objective: Posterior reversible encephalopathy syndrome (PRES) is associated with immunosuppressive agents used in children with haemato-oncological diseases. There are no reports to date from the South Asia and South East Asia region. We report a Malaysian tertiary centre case series of children with haemato-oncological disease who developed PRES. Methods: Retrospective study of children seen with haemato-oncology diseases seen at the University Malaya Medical Centre Kuala Lumpur who developed PRES from 2011 – 2013. Clinical details were obtained from medical records and brain neuroimaging was reviewed. Results: Five patients met the inclusion criteria. All 5 patients had significant hypertension acutely or subacutely prior to neurology presentation. Four presented with acute seizures and the remainder 1 presented with encephalopathy.Three patients were on chemotherapy, 1 had renal impairment and 1 had prior immunosupression for bone marrow transplantation. A full recovery was seen in 4 patients and 1 patient had mild residual quadriplegia. Conclusion: Our case series expands the clinico-radiological spectrum of PRES in children with underlying haemato-oncological disorders. It is the first to show that prior cyclosporin intake as long as 2 months is a potential risk factor for PRES. Clinicians need to be vigilant for development of PRES and closely monitor the blood pressure in these children who are receiving or recently had immunosuppressive drugs and present with acute neurological symptoms.

Original languageEnglish
Pages (from-to)275-281
Number of pages7
JournalNeurology Asia
Volume20
Issue number3
Publication statusPublished - 1 Sep 2015
Externally publishedYes

Fingerprint

Posterior Leukoencephalopathy Syndrome
Pediatrics
Immunosuppressive Agents
Blood Pressure Monitors
Quadriplegia
Far East
Malaysia
Brain Diseases
Neurology
Bone Marrow Transplantation
Neuroimaging
Cyclosporine
Medical Records
Seizures
Retrospective Studies
Hypertension
Kidney
Drug Therapy
Brain
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Fong, C. Y., Hlaing, C. S., Aye, A. M. M., Tay, C. G., Ariffin, H., & Ong, L. C. (2015). Posterior reversible encephalopathy syndrome: Malaysian haemato-oncological paediatric case series. Neurology Asia, 20(3), 275-281.

Posterior reversible encephalopathy syndrome : Malaysian haemato-oncological paediatric case series. / Fong, Choong Yi; Hlaing, Chaw Su; Aye, Aye Mya Min; Tay, Chee Geap; Ariffin, Hany; Ong, Lai Choo.

In: Neurology Asia, Vol. 20, No. 3, 01.09.2015, p. 275-281.

Research output: Contribution to journalArticle

Fong, CY, Hlaing, CS, Aye, AMM, Tay, CG, Ariffin, H & Ong, LC 2015, 'Posterior reversible encephalopathy syndrome: Malaysian haemato-oncological paediatric case series', Neurology Asia, vol. 20, no. 3, pp. 275-281.
Fong CY, Hlaing CS, Aye AMM, Tay CG, Ariffin H, Ong LC. Posterior reversible encephalopathy syndrome: Malaysian haemato-oncological paediatric case series. Neurology Asia. 2015 Sep 1;20(3):275-281.
Fong, Choong Yi ; Hlaing, Chaw Su ; Aye, Aye Mya Min ; Tay, Chee Geap ; Ariffin, Hany ; Ong, Lai Choo. / Posterior reversible encephalopathy syndrome : Malaysian haemato-oncological paediatric case series. In: Neurology Asia. 2015 ; Vol. 20, No. 3. pp. 275-281.
@article{599f65d808324b8fb55a4e032cf0776a,
title = "Posterior reversible encephalopathy syndrome: Malaysian haemato-oncological paediatric case series",
abstract = "Background & Objective: Posterior reversible encephalopathy syndrome (PRES) is associated with immunosuppressive agents used in children with haemato-oncological diseases. There are no reports to date from the South Asia and South East Asia region. We report a Malaysian tertiary centre case series of children with haemato-oncological disease who developed PRES. Methods: Retrospective study of children seen with haemato-oncology diseases seen at the University Malaya Medical Centre Kuala Lumpur who developed PRES from 2011 – 2013. Clinical details were obtained from medical records and brain neuroimaging was reviewed. Results: Five patients met the inclusion criteria. All 5 patients had significant hypertension acutely or subacutely prior to neurology presentation. Four presented with acute seizures and the remainder 1 presented with encephalopathy.Three patients were on chemotherapy, 1 had renal impairment and 1 had prior immunosupression for bone marrow transplantation. A full recovery was seen in 4 patients and 1 patient had mild residual quadriplegia. Conclusion: Our case series expands the clinico-radiological spectrum of PRES in children with underlying haemato-oncological disorders. It is the first to show that prior cyclosporin intake as long as 2 months is a potential risk factor for PRES. Clinicians need to be vigilant for development of PRES and closely monitor the blood pressure in these children who are receiving or recently had immunosuppressive drugs and present with acute neurological symptoms.",
author = "Fong, {Choong Yi} and Hlaing, {Chaw Su} and Aye, {Aye Mya Min} and Tay, {Chee Geap} and Hany Ariffin and Ong, {Lai Choo}",
year = "2015",
month = "9",
day = "1",
language = "English",
volume = "20",
pages = "275--281",
journal = "Neurology Asia",
issn = "1823-6138",
publisher = "ASEAN Neurological Association",
number = "3",

}

TY - JOUR

T1 - Posterior reversible encephalopathy syndrome

T2 - Malaysian haemato-oncological paediatric case series

AU - Fong, Choong Yi

AU - Hlaing, Chaw Su

AU - Aye, Aye Mya Min

AU - Tay, Chee Geap

AU - Ariffin, Hany

AU - Ong, Lai Choo

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Background & Objective: Posterior reversible encephalopathy syndrome (PRES) is associated with immunosuppressive agents used in children with haemato-oncological diseases. There are no reports to date from the South Asia and South East Asia region. We report a Malaysian tertiary centre case series of children with haemato-oncological disease who developed PRES. Methods: Retrospective study of children seen with haemato-oncology diseases seen at the University Malaya Medical Centre Kuala Lumpur who developed PRES from 2011 – 2013. Clinical details were obtained from medical records and brain neuroimaging was reviewed. Results: Five patients met the inclusion criteria. All 5 patients had significant hypertension acutely or subacutely prior to neurology presentation. Four presented with acute seizures and the remainder 1 presented with encephalopathy.Three patients were on chemotherapy, 1 had renal impairment and 1 had prior immunosupression for bone marrow transplantation. A full recovery was seen in 4 patients and 1 patient had mild residual quadriplegia. Conclusion: Our case series expands the clinico-radiological spectrum of PRES in children with underlying haemato-oncological disorders. It is the first to show that prior cyclosporin intake as long as 2 months is a potential risk factor for PRES. Clinicians need to be vigilant for development of PRES and closely monitor the blood pressure in these children who are receiving or recently had immunosuppressive drugs and present with acute neurological symptoms.

AB - Background & Objective: Posterior reversible encephalopathy syndrome (PRES) is associated with immunosuppressive agents used in children with haemato-oncological diseases. There are no reports to date from the South Asia and South East Asia region. We report a Malaysian tertiary centre case series of children with haemato-oncological disease who developed PRES. Methods: Retrospective study of children seen with haemato-oncology diseases seen at the University Malaya Medical Centre Kuala Lumpur who developed PRES from 2011 – 2013. Clinical details were obtained from medical records and brain neuroimaging was reviewed. Results: Five patients met the inclusion criteria. All 5 patients had significant hypertension acutely or subacutely prior to neurology presentation. Four presented with acute seizures and the remainder 1 presented with encephalopathy.Three patients were on chemotherapy, 1 had renal impairment and 1 had prior immunosupression for bone marrow transplantation. A full recovery was seen in 4 patients and 1 patient had mild residual quadriplegia. Conclusion: Our case series expands the clinico-radiological spectrum of PRES in children with underlying haemato-oncological disorders. It is the first to show that prior cyclosporin intake as long as 2 months is a potential risk factor for PRES. Clinicians need to be vigilant for development of PRES and closely monitor the blood pressure in these children who are receiving or recently had immunosuppressive drugs and present with acute neurological symptoms.

UR - http://www.scopus.com/inward/record.url?scp=84943237938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943237938&partnerID=8YFLogxK

M3 - Article

VL - 20

SP - 275

EP - 281

JO - Neurology Asia

JF - Neurology Asia

SN - 1823-6138

IS - 3

ER -